TABLE 3.

Overall survival (OS) and metastasis-free survival (MFS) after PSA recurrence, stratified by PSA doubling time

Overall survival (OS)				Metastasis-free survival (MFS)
	PSADT <3 months (n = 7)	PSADT 3–9 months (n = 59)	PSADT ≥9 months (n = 280)		PSADT <3 months (n = 7)	PSADT 3–9 months (n = 38)	PSADT ≥9 months (n = 145)
Median OS (years)	3.4	16.1	>23.0*	Median MFS (years)	1.4	4.0	>15.0*
95% CI	(3.3–4.7)	(11.5, >23.0)	(NA, >23.0)	95% CI	(0.7, 1.5)	(1.7–5.9)	(8.8, >15.0)
OS rate (%) at 5 years	0	82	93	MFS rate (%) at 5 years	0	31	87
95% CI	(0.00–0.60)	(0.67–0.90)	(0.89–0.95)	95% CI	(0.0–0.56)	(0.12–0.52)	(0.76–0.94)
OS rate (%) at 10 years	NA	68	83	MFS rate (%) at 10 years	NA	12	54
95% CI	NA	(0.51–0.80)	(0.77–0.88)	95% CI	NA	(0.1–0.38)	(0.24–0.78)
OS rate (%) at 15 years	NA	46	75	MFS rate (%) at 15 years	NA	NA	NA
95% CI	NA	(0.17–0.71)	(0.66–0.82)	95% CI	NA	NA	NA

In each subgroup, the median OS/MFS as well as the 5-, 10- and 15-year probability of OS/MFS from the time of PSA recurrence are shown. PSADT, prostate-specific antigen doubling time; NA, not applicable.

^*Median survival not reached.